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Rapid in vivo measurement of β-amyloid reveals biphasic
clearance kinetics in an Alzheimer’s mouse model
Carla M. Yuede,1 Hyo Lee,1 Jessica L. Restivo,1 Todd A. Davis,1 Jane C. Hettinger,1 Clare E. Wallace,1
Katherine L. Young,1 Margaret R. Hayne,1 Guojun Bu,2 Chen‑zhong Li,3 and John R. Cirrito1
1
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Department of Neurology, Hope Center for Neurological Disorders, Knight Alzheimer’s Disease Research Center, Washington University School of Medicine,
St. Louis, MO 63110
2
Department of Neuroscience, Mayo Clinic, Jacksonville, FL 32224
3
Nanobioengineering/Bioelectronics Laboratory, Department of Biomedical Engineering, Florida International University, Miami, FL 33199

F indings from genetic, animal model, and human studies support the observation that accumulation of the β-amyloid (Aβ)
peptide in the brain plays a central role in the pathogenic cascade of Alzheimer’s disease (AD). Human studies suggest that one
key factor leading to accumulation is a defect in brain Aβ clearance. We have developed a novel microimmunoelectrode (MIE)
to study the kinetics of Aβ clearance using an electrochemical approach. This is the first study using MIEs in vivo to measure
rapid changes in Aβ levels in the brains of living mice. Extracellular, interstitial fluid (ISF) Aβ levels were measured in the
hippocampus of APP/PS1 mice. Baseline levels of Aβ40 in the ISF are relatively stable and begin to decline within minutes of
blocking Aβ production with a γ-secretase inhibitor. Pretreatment with a P-glycoprotein inhibitor, which blocks blood–brain
barrier transport of Aβ, resulted in significant prolongation of Aβ40 half-life, but only in the latter phase of Aβ clearance from
the ISF.
Accumulation of β-amyloid (Aβ) in the brain is an initiating factor in the pathological cascade leading to the development and progression of Alzheimer’s disease (AD; Musiek
and Holtzman, 2015). High concentrations of Aβ promote its
aggregation into toxic species, such as oligomers and fibrils,
within the brain extracellular space. The balance between Aβ
generation and elimination determines the concentration
of Aβ in the brain interstitial fluid (ISF). Four broad pathways have been identified that eliminate Aβ from the brain:
transport across the blood–brain barrier (BBB), proteolytic
degradation, cellular uptake, and bulk flow clearance. Several of these pathways are impaired in individuals with AD
(Preston et al., 2003; Nixon, 2007; van Assema et al., 2012).
For instance, neprilysin and P-glycoprotein, an Aβ-degrading
enzyme and an Aβ transporter at the BBB, respectively, are
significantly reduced in human AD brain (Wang et al., 2005;
Deo et al., 2014). In mouse models, deletion of either of these
proteins increases brain Aβ levels, increases plaque load, and
significantly prolongs the elimination rate of Aβ (or halflife) from the brain (Cirrito et al., 2005; Farris et al., 2007).
Clearance of Aβ from the CSF is impaired in individuals with
AD (Mawuenyega et al., 2010), strongly suggesting that a key
factor leading to Aβ accumulation is a defect in eliminating
the peptide from the brain. Aβ is secreted into the extracellular space, where it is soluble in the ISF under normal
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circumstances. The ISF pool of Aβ gives rise to pathological
species, so mechanisms that regulate Aβ clearance from the
ISF should impact AD pathogenesis. Aβ has a relatively short
half-life compared with other proteins in the brain, indicating that some clearance mechanisms are fast-acting. Here, we
use a novel microimmunoelectrode (MIE) to measure rapid
changes in ISF Aβ metabolism in vivo.
Studying the temporal kinetics of Aβ within the brain
ISF requires specialized techniques that specifically sample Aβ
only from the ISF with the exclusion of peptide in other
brain compartments (e.g., intracellular or membrane-bound)
and can measure Aβ serially over time in a living mouse. In
the past, we pioneered an in vivo microdialysis technique
to measure ISF Aβ levels every 60 min over 3–5 d in mice
(Cirrito et al., 2003, 2011). Although hourly sampling is still
very useful, some studies require even faster temporal resolution. We recently developed an electrochemical technique
using MIEs to detect Aβ (Prabhulkar et al., 2012) and have
adapted it to measure ISF Aβ every 60 s over several hours in
the brains of living mice.
RESULTS AND DISCUSSION
In vitro characterization of the MIE
Amperometry is an electrochemical technique used to measure oxidation of a wide range of molecules, most notably
small molecules such as serotonin and dopamine in the brain
(Wightman, 1988). Several national security biohazard de© 2016 Yuede et al. This article is distributed under the terms of an Attribution–Noncommercial–Share
Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org
/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–
Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Figure 1. Aβ-specific MIE. (A) Schematic
of MIE. Anti-Aβ antibodies are covalently attached to the electrode surface, and then unbound space is blocked with BSA. An electrode
held at 0.65 V induces oxidation of Tyr amino
acids. Oxidation releases an electron that the
carbon fiber detects as current. The amount
of current is proportional to the amount of
Tyr present. Because many proteins in the extracellular space contain Tyr residues, the inclusion of an anti-Aβ antibody is a necessary
factor that determines specificity of the electrode. (B) Peak oxidation current of Aβ MIE in
matched concentrations of human and mouse
Aβ (n = 3; mean ± SEM).

tectors, such as for anthrax, use amperometry in combination with antibodies to make the chip-based sensors specific
for a protein (Sadik et al., 2003). We have developed a similar amperometric, antibody-based approach to measure Aβ;
however, these sensors can quantify a wide range of concentrations, take longitudinal measurements, and be implanted
directly into the brain.
Aβ peptides in solution can be measured by exploiting
the intrinsic electroactivity of Aβ (Vestergaard et al., 2005).
The single tyrosine (Tyr) residue at position 10 of human Aβ
bears a phenolic group that can be oxidized at an electrode
surface. Oxidation releases electrons, which an electrode detects as current; the amount of current is directly proportional
to the number of Tyr residues present, or the concentration.
Using square wave voltammetry (SWV), the voltage applied
to a carbon fiber microelectrode is step-wise increased from
0 to 1.0 V. When the electrode scans through ∼0.65 V, Tyr
residues present in human Aβ oxidize, which is detected by
the electrode as increased peak oxidation current. However, a
0.65-V potential will oxidize a variety of molecules, including all nearby Tyr within other proteins. We covalently attached anti-Aβ40 or anti-Aβ42 antibodies, mHJ2 and mHJ7.4,
respectively, to the MIE surface to provide specificity for each
target (Fig. 1 A). Albumin is then absorbed to the electrode
surface to limit nonspecific signal.Tyr oxidation is irreversible,
therefore, Aβ peptides oxidized at the electrode surface can
only be measured once. Additionally, once the tyrosine amino
acids within albumin and antibody are initially oxidized, they
will not contribute signal to the MIE over time.
The Aβ MIE is a 5-µm-diam, 30–60-µm-long cylindershape similar to the carbon fiber microelectrodes used in other
in vivo studies (Roitman et al., 2008). Murine Aβ lacks a Tyr at
position 10, so in theory, should not produce an oxidative signal
using the MIE. As expected, robust oxidative signal is detected
with the MIE in a solution of human Aβ, whereas only negligible signal is observed in a concentration-matched solution
of murine Aβ (Fig. 1 B). Post-hoc ELISAs were used to verify
that the absolute concentration of murine and human Aβ were
equal in these solutions. Importantly, the mHJ2 anti-Aβ40 anti678

body on the MIE binds to both mouse and human Aβ equally.
Consequently, murine Aβ and wild-type mice serve as important negative controls to identify how specific the MIEs are at
detecting only human Aβ as opposed to other electroactive
molecules and proteins.
The antibody attached to the electrode is particularly
important, as it provides specificity for the target and strongly
influences MIE longevity. For the MIE to function, there
must be excess antibody capable of binding fresh target; however, if all of the antibodies are bound to Aβ, the electrode
becomes nonfunctional. MIEs are an application in which
antibodies with a moderate affinity are ideal, so that the target
has both an on-rate as well as a reasonable off-rate, allowing
antibody binding capacity to remain open so new Aβ continues to bind. To prolong longevity of the MIE, we used
an antibody specific for Aβ40 with moderate affinity (mHJ2
KD = 14 nM determined by surface plasmon resonance) to
allow for dissociation.
For our initial in vitro studies, we attached a mouse
monoclonal antibody specific for Aβ40 (mHJ2) and evaluated
the electrode response in solutions of Aβ40 and Aβ42 using SWV.
Oxidation peak height increased as concentration of Aβ40 increased (Fig. 2 A). At comparable concentrations in solution,
the Aβ40 MIE is 52 times more selective for Aβ40 over Aβ42
(Fig. 2 B). Similarly, attaching mHJ7.4, an anti-Aβ42–specific
antibody, we also saw an increase in peak height corresponding with increasing concentrations (Fig. 2 C).The Aβ42 MIE is
15,000 times more selective for Aβ42 than for Aβ40 (Fig. 2 D).
The higher selectivity of the Aβ42 MIE is likely caused by the
higher affinity of the antibody. This difference in selectivity is
particularly important in vivo, where there are very low concentrations of Aβ42 compared with Aβ40.We have intentionally
designed the MIEs to have widely different selectivity for Aβ40
and Aβ42 species to take into account practical considerations
of electrode longevity and actual 40:42 ratios of the peptide in
brain ISF. In the APP/PS1 mouse model used in these studies,
the concentration of brain ISF Aβ42 is 10-fold lower than Aβ40.
Consequently, the Aβ40 MIE actually has an effective 520-fold
selectivity for Aβ40 versus Aβ42 in vivo.
Rapid measurement of Aβ clearance in vivo | Yuede et al.

Figure 2. In vitro characterization of MIEs for Aβ40 and Aβ42. Oxidation peak height of MIEs coated with either (A) an Aβ40 specific antibody (mHJ2;
n = 6) or (C) Aβ42-specific antibody (mHJ7.4; n = 7). (B) Representative concentration of Aβ measured using Aβ40 MIE in matched concentrations of Aβ40 and
Aβ42 (n = 3; mean ± SEM). Representative concentration of Aβ measured using Aβ42 MIE in matched concentrations of Aβ40 and Aβ42 (n = 3; mean ± SEM; D).

In vivo MIEs to measure brain ISF Aβ
To measure rapid changes in brain ISF Aβ in the mouse hippocampus, we stereotaxically implanted Aβ40 MIEs into the
hippocampus of anesthetized APP/PS1 and wild-type mice
(Fig. 3 A). A large oxidation peak is observed at ∼0.65 V in
APP/PS1 mice, whereas only a negligible oxidative signal
is seen in scans of wild-type mice (Fig. 3 B). Variability in
individual MIE length and sensitivity leads to variable oxidation peak heights for each electrode; therefore, each MIE
must be calibrated against known concentrations of Aβ. The
mean concentration of human Aβ40 in the ISF, as measured
by the MIE, is 128.16 ng/ml. Within a single animal, the
minute-to-minute variability of Aβ is 9.89 ± 1.88 ng/ml
(mean ± SEM). These fluctuations appear to be biologically
driven by rapid changes in Aβ production and clearance. In
contrast, levels of murine Aβ in wild-type mice are essentially
undetectable (Fig. 3 C). From these data, we infer that the
MIE is at least 8,000-fold more selective in vivo for human
Aβ as opposed to any other Tyr present in the brain ISF.
To evaluate stability of the MIE in vivo over time, we
normalized the concentration of ISF Aβ at each time point
to the mean baseline concentration from minute 10 to 25 for
each mouse (Fig. 3 D). Concentrations are stable until minute
118, after which measurements have a small but significant
decrease from baseline levels (P = 0.02).These results indicate
that the MIE loses sensitivity after ∼2 h in vivo; therefore,
measurements beyond 120 min need to be corrected for this
decease. The decrease in ISF Aβ after 2 h appears to be priJEM Vol. 213, No. 5

marily a result of electrode sensitivity and possibly a small reduction in ISF Aβ levels caused by anesthesia. To verify using
a complementary technique, we used in vivo microdialysis
to measure ISF Aβ every hour before and during isoflurane
anesthesia. ISF Aβ levels decrease by 14% during the first 3 h
of isoflurane anesthesia; however, this was not a significant
change in Aβ (n = 4, P = 0.135). For the following MIE
studies, we only sampled Aβ for 100 min after implantation
to avoid this confounding factor.
MIE technology
MIEs provide a powerful technology to assess the rapid dynamics of protein changes in brain within short periods. This
provides a temporal resolution to measure proteins in vivo
every 60 s, which was previously not feasible. One of the advantages, and disadvantages, of the Aβ MIE technique is that
it only detects human Aβ species. Although wild-type mice
serve as a negative control, this technique limits studies to
those involving transgenic/knock-in mouse models that produce the human form of Aβ. The 5-µm-diam of the MIEs is
smaller than most neuron cell bodies, so the electrodes create
very little damage during insertion. Implantation of microelectrodes has been shown to activate microglia within 6 h,
but not within the short timeframe of our study (Kozai et al.,
2012). We examined tissue sections for evidence of lesions or
microbleeds resulting from acute MIE implantation; in many
cases tissue disruption caused by surgery was evident on the
brain surface; however, the exact site of the MIE tip was very
679

Figure 3. In vivo MIE measures ISF Aβ in
APP/PS1 mouse model. (A) Stereotaxic placement of MIE, reference and counter electrodes
on mouse skull, with representative SWV peaks
from the hippocampus of an APP/PS1 mouse
and WT littermate. (B) Traces measuring
human and murine Aβ with baseline subtraction are shown on the same scale to highlight
the differences in peak height observed, while
inset shows background level detected in the
WT mouse. (C) ISF Aβ40 concentrations over
180 min in APP/PS (n = 6) and WT (n = 3) mice.
(D) Data in Panel C normalized to percent of
baseline ISF Aβ40 levels of each APP/PS1 mouse
show stable levels until 118 min after MIE insertion (ANOVA post hoc analysis, P = 0.02).

small and normally undetectable by histology. Consequently,
tissue damage is only a small concern using this technique.
MIEs only function for 2 h before starting to lose sensitivity. In contrast, our in vivo microdialysis technique samples
Aβ every hour, but lasts for 3–5 d (Cirrito et al., 2003). The
MIE and microdialysis approaches complement each other
by enabling the study of both brief and prolonged events that
regulate ISF Aβ metabolism. Measuring protein concentrations every 60 s enables us to study fast-acting mechanisms for
Aβ production and clearance, which could not previously be
studied. Specificity of the electrode depends on the antibody
attached and the presence of an electroactive amino acid (such
as tyrosine, tryptophan, or cysteine); therefore, it is possible
that MIEs can be developed to detect other proteins as well.
Rapid measurement of Aβ half-life in vivo
P-glycoprotein (Pgp) removes brain ISF Aβ by transporting
it across the BBB (Cirrito et al., 2005; Hartz et al., 2010).
Pgp is expressed on the luminal surface of brain endothelial
cells and transports the peptide out of those cells and into
blood. Pgp-null mice (mdr1a/1b double knockout mice)
have significantly impaired BBB transport of Aβ40; however,
Aβ42 transport is minimally affected. Pgp-null mice crossed to
Tg2576 APP transgenic mice also have significantly greater
plaque load, and similarly, individuals with low Pgp expression
have higher Aβ deposits in brain (Vogelgesang et al., 2002).
Using MIEs to measure real-time and rapid changes in
ISF Aβ40, we evaluated clearance under normal conditions
and after Pgp inhibition. Previous studies in rodents have
shown XR9576 effectively blocks Pgp-mediated transport
quickly, with maximum activity inhibited 30 min after injection, which then declines slowly due to low compound
elimination (Bankstahl et al., 2008). We measured levels of
680

XR9576 in brain tissue at 1 h after injection and found mean
levels to be 533.0 ± 68.11 µM, where the IC50 for inhibition
in vivo is 1.05 µM (Wanek et al., 2015). Therefore, we pretreated one group of APP/PS1 mice with XR9576 for 1 h
before measuring Aβ40 clearance. Under anesthesia, we inserted an Aβ40 MIE into the hippocampus to measure baseline
ISF Aβ levels for 15 min before administering Compound E,
a γ-secretase inhibitor (GSI), to block Aβ generation. Inhibiting Pgp alone resulted in a 305% increase in baseline levels
of Aβ40 compared with controls (Fig. 4 A). The increase in
ISF Aβ detected with the MIE is much greater than previous
studies using microdialysis (Cirrito et al., 2005). This is likely
because of the difference of awake versus anesthetized mice
and because the two techniques detect slightly different populations of ISF Aβ in vivo.
Treating mice with a GSI rapidly blocks Aβ generation, enabling us to assess the elimination of existing peptide
present within the ISF. From these data, we can calculate an
in vivo elimination half-life of endogenous Aβ. Although
the absolute levels of Aβ40 were significantly higher in the
XR9576-treated mice, ISF Aβ40 concentration still declined
quickly after GSI treatment in both groups (Fig. 4 B). Compound E drug levels reach 395 nM brain tissue within 5 min
after intraperitoneal injection (Fig. 4 C). This concentration is ∼1,200-fold higher than the IC50 of Compound E to
block APP cleavage into Aβ (IC50 in CHO cells is 300 pM;
Seiffert et al., 2000). Compound E levels in the brain decrease substantially by 60 min after injection; however, they
still remain 30-fold higher than the IC50 (Fig. 4 C). Percent
changes in ISF Aβ40 after GSI administration were transformed into log values to calculate rate of clearance over
time (Fig. 4 D). We analyzed the overall rate of clearance
in both groups from minutes 5–60, which was significantly
Rapid measurement of Aβ clearance in vivo | Yuede et al.

Figure 4. Rapid measurement of ISF Aβ40 clearance after Pgp inhibition. (A) Absolute baseline concentrations of ISF Aβ40 calculated using calibrated
MIEs in the hippocampus of APP/PS1 mice are significantly increased (Student’s t test; *, P = 0.008) 60 min after XR9576 treatment (n = 8; mean = 283.9
± 80.38; 80 mg/kg) compared with control mice (n = 15; mean = 99.12 ± 19.28). (B) ISF Aβ40 concentrations decrease in both groups after Compound E
administration to block Aβ production. (C) Compound E levels in the brain reach ∼1,200-fold IC50 within 5 min of injection and remain ∼30-fold higher
than IC50 at 60 min. (D) Log plot of percent Aβ change from baseline versus time for both XR9576-treated mice (n = 5) and control (n = 6) shows initial rates
of clearance are very similar then begin to diverge 16 min after γ-secretase inhibition. (E) Overall half-life of Aβ40 is significantly slowed (Student’s t test;
*, P = 0.016) after XR9576 treatment (control mean = 23.30 ± 4.55 min; XR9576 mean, 71.05 ± 16.01 min). Further analysis of the slopes between groups
suggests two phases in Aβ40 clearance over time. Statistical analysis reveals no difference in rates over the first 15 min (F; Student’s t test, P = 0.698; control
mean = 22.26 ± 4.09 min; XR9576 mean, 27.1 ± 12.41 min); however, rates from 16–60 min are significantly slowed in XR9576-treated mice (G; Student’s
t test; *, P = 0.001; control mean, 30.44 ± 7.71 min; XR9576 mean, 84.08 ± 10.85 min). Error bars represent ± SEM.

prolonged by 275% in the XR9576-treated mice compared
with control mice (P = 0.012; Fig. 4 E). The overall pattern
of changes observed in ISF Aβ after GSI administration and
Pgp inhibition using the MIE are comparable to what we
have previously reported (Cirrito et al., 2005).
Interestingly, however, the rates of clearance were not
uniformly different throughout the entire course of the study;
the semi-log plots of both groups actually show similar clearance rates up until 15 min, where they then begin to diverge
(Fig. 4 D). Using a modified curve stripping analysis, we isolated two different slopes in the clearance profile. We found
no significant differences in the clearance rate during the initial 15 min after GSI treatment (Fig. 4 F); however, the second
phase in the clearance rate (minutes 16–60) was significantly
slower in XR9576-treated mice (P = 0.001; Fig. 4 G). To
determine if acute inhibition of Pgp influenced expression of
low-density lipoprotein-1 (LRP1), or other genes related to
APP processing or Aβ clearance, we examined mRNA levels
in brain tissue 2 h after XR9756 treatment (see Materials and
JEM Vol. 213, No. 5

methods for specific genes). We did not find significant differences in mRNA expression levels in the brain, indicating
the drug treatment is not affecting global expression of genes
related to APP processing or Aβ elimination (n = 6/group;
P = 0.08–0.94; cut off for multiple comparisons, P = 0.004).
Similarly, LRP1 protein levels did not change in hippocampus after XR9576 administration (n = 9/group, P = 0.35).
However, we did not assess expression in blood vessels specifically. Pgp does not appear to play a substantial role in brain Aβ
clearance at high concentrations, but is a critical mechanism
when Aβ levels decrease below a certain threshold.
Kinetics of Aβ clearance in vivo
Clearance of Aβ falls into four main categories: active BBB
transport into the periphery, cellular uptake, proteolytic degradation, and passive bulk flow elimination. Both LRP1 and
Pgp are expressed by endothelial cells (abluminally and luminally, respectively) and act cooperatively to transport Aβ
from the perivascular space out of the brain into blood (Shi681

bata et al., 2000; Deane et al., 2004; Zlokovic et al., 2010).
LRP1 and several family members have an additional role
of cellular uptake of Aβ within the brain (Castellano et al.,
2012; Kanekiyo et al., 2013). Proteases such as neprilysin and
matrix metalloproteinases (MMPs) degrade extracellular Aβ
(Farris et al., 2007). Lastly, bulk flow mechanisms, including
the glymphatic system, clear Aβ out of the ISF as part of the
normal, passive fluid turnover (Xie et al., 2013).
By measuring ISF Aβ very rapidly, we were able to detect multiple rates of Aβ elimination from the brain. Our data
using MIEs for rapid sampling determined that Aβ clearance
does not follow first-order kinetics, as previously reported by
our group using microdialysis (Cirrito et al., 2003). Instead,
the rate of elimination varies with concentration. The initial
rate of clearance, when ISF Aβ concentrations are high, has
a very short half-life. However, as Aβ concentrations decline,
the half-life is significantly longer. It is possible that the various Aβ clearance mechanisms contribute to different clearance rates. It will be necessary to explore these effects by
blocking individual pathways and measuring rapid clearance
to determine the role each mechanism plays in the immediate
removal of Aβ from the ISF. Our data demonstrate that Pgp
is critical for the slower elimination rate of Aβ at the BBB,
which appears to account for an overall greater percentage
of ISF Aβ clearance than the faster pathway. These results are
similar to those reported by (Qosa et al., 2014) in that BBB
clearance accounts for a greater percentage of Aβ40 clearance
than proteolytic degradation, and Pgp inhibition slows this
clearance pathway specifically.
Our data suggest that the speed and efficiency of Aβ
clearance pathways may be different. A therapeutic strategy
aimed at rapid clearance at only high concentrations may be
different than a strategy that is designed for a sustained, possibly larger, suppression of Aβ. And if multiple pathways are
targeted, then enhancing clearance mechanisms with different
properties and rates could be beneficial.
MATERIALS AND METHODS
Animals. All experimental procedures involving animals
were approved by the Animal Studies Committee at Washington University. We bred APP/PS1+/− hemizygous mice
(Jankowsky et al., 2004) to wild-type C3H/B6 mice (The
Jackson Laboratory), and then used the APP/PS1+/− offspring, or wild-type littermates, for experiments at 3 mo
of age, before Aβ deposits are observed in this model. These
mice contain a PS1ΔE9 mutation and human APP Swedish
mutation that were inserted into a single locus. Animals were
screened for the PS1 and APP transgenes by polymerase
chain reaction from tail DNA. Male and female littermate
mice were distributed between experimental groups.
MIE preparation.MIEs were prepared following our previously described methods (Prabhulkar et al., 2012). Carbon
fiber microelectrodes were used as the platform sensor because of their high signal-to-noise ratio, biological compati682

bility, and small size. Carbon-based electrodes have also been
proven to sensitively detect Tyr oxidation (Vestergaard et al.,
2005). In brief, a single length of carbon fiber (5-µm-diam;
GoodFellow Corp.) was aspirated into a glass capillary tube
(0.4-mm inner diameter, 4 inch length; A-M Systems), shaped
using a pipette puller (Narishige PE-22), and attached to an
insulated silver wire using conductive silver adhesive paste
(Ted Pella, Inc.). The junction between the wire and the glass
capillary tube was sealed using heat shrink tubing (NTE
Electronics). The carbon fiber was cut using microsurgical
scissors (World Precision Instruments, Inc.) to a length of
30–60 µm. To enhance binding of the capture antibody, the
microelectrodes were pretreated using a triangular waveform
from 0 to 3 V for 70 s in PBS, or in 150 mM NaCl solution
(pH, 10) at 1.2 V for 4 min. The carboxylic groups on the
carbon fiber surface were activated by application of 0.4 M of
EDC and 0.1 M of NHSS solutions (Thermo Fisher Scientific) to form a semistable reactive amine NHS ester. The activated microelectrodes are placed in a solution of antibody
(e.g., mHJ2 for Aβ40 or mHJ7.4 for Aβ42) and incubated at
room temp for 10 min, and then 4°C overnight. After antibody attachment, MIEs were incubated with 0.05% ethanolamine to deactivate reactive amine sites and then 0.1% BSA
to block nonspecific protein-binding sites.
In vitro MIE studies.In vitro calibration of the MIEs before
experiments were conducted using a CH Instruments 660D
Electrochemical Workstation with PicoAmp booster (CH Instruments Inc.). A conventional three-electrode cell consisting
of an Ag/AgCl reference electrode (1 M KCl), and a platinum
wire as a counter electrode was used in all experimental procedures. Synthetic human Aβ40, Aβ42, and mouse Aβ40 (American Peptide Co.) were prepared in fivefold serial dilutions
ranging from 1 µg to 64 pg in 0.1% BSA in PBS. SWV was
used to monitor the response of the electrode in different
concentrations of Aβ. Actual concentration in each Aβ sample
was determined by sandwich ELISA after each experiment.
Aβ concentrations using the MIE were calculated based on
standard curve values from the calibration ELISA. SWV parameters used were: Init E (V) = 0; Final E (V) = 1; Inc.r E
(V) = 0.004; Amplitude (V) = 0.04; and Frequency (Hz) = 15.
In vivo MIE studies.To maintain consistency with our in vitro
characterization of the Aβ40 MIE, we used a three electrode
design in vivo as well. In addition to the MIE, a stainless steel
bone screw used as a counter electrode, and an Ag/AgCl reference electrode (InVivo Metrics) were implanted into the
brain of preplaque (3–4 mo old) APP/PS1+/− transgenic mice
and wild-type littermates. All electrodes were stereotaxically
implanted in to the brains of APP/PS1+/− mice under isoflurane anesthesia. Mice were placed on a heating pad to maintain body temperature. For these experiments, Aβ40 MIEs
were inserted into the hippocampus at coordinates: bregma
–3.1 mm, 2.6 mm lateral to midline, and 1.7 mm below
dura mater. Repetitive SWV scans were run every 60 s for
Rapid measurement of Aβ clearance in vivo | Yuede et al.

up to 180 min. The stereotax was enclosed in a faraday cage
to reduce electrical noise. Electrodes were attached to a CH
Instruments 830D Electrochemical Analyzer with PicoAmp
booster. All electrodes were calibrated against known concentrations of Aβ40 before the experiment, and only MIEs
showing increasing response to increasing concentrations of
Aβ40 in vitro were used for in vivo experiments.
Aβ ELISA. ISF Aβ levels were assessed using sandwich ELI
SAs as previously described (Cirrito et al., 2011). In brief, to
assess Aβ40 and Aβ42 in MIE calibration solutions, mouse
monoclonal antibodies (HJ2 or HJ7.4, respectively) were
used to capture and a biotinylated central domain Aβspecific antibody (HJ5.1) was used to detect, followed by
streptavidin-poly-HRP-20 (Fitzgerald Industries). All ELI
SA assays were developed using Super Slow ELISA TMB
(Sigma-Aldrich) and absorbance read on an Epoch plate
reader (Bio-Tek) at 650 nm.
Aβ elimination half-life.ISF Aβ half-life was determined similar to our previously described method using microdialysis
(Cirrito et al., 2003). MIEs were inserted into the hippocampus and SWV scans were run until the baseline became stable
(10–20 min). After baseline stabilization, mice were administered a potent, blood–brain permeable γ-secretase inhibitor,
Compound E (synthesized by AsisChem; 30 mg/kg) intraperitoneally to rapidly block Aβ production. ISF Aβ levels were
measured by SWV scans every 60 s for 60–90 min.The half-life
of ISF Aβ was calculated on the basis of the slope of the semilog
plot of percent change in Aβ versus time. Only Aβ values that
were continually decreasing were included in half-life analysis
(within the 60 min after Compound E administration).
Quantitative real-time PCR (qRT-PCR).3-mo-old mice were
treated with XR9576 (80 mg/kg i.v.) or vehicle (equal volume
5% dextrose). Mice were sacrificed 2 h later, and their brains
were microdissected and frozen on dry ice. Total RNA were
extracted from cortex using the RNeasy Mini kit (QIAGEN)
and reverse transcribed using the High Capacity cDNA Reverse Transcription kit (Invitrogen). The APP processingrelated genes evaluated were as follows: Amyloid precursor protein (APP), Presenilin 1 and 2 (PSEN1 and PSEN2)
Nicastrin, Anterior pharynx-defective 1 (APH-1), β-secretase
1 (BACE1), A Disintegrin and metalloproteinase domaincontaining protein 10 and 17 (ADAM10 and ADAM17).
The Aβ clearance-related genes evaluated were as follows:
P-glycoprotein (Pgp), low density lipoprotein 1 (LRP1), insulin degrading enzyme (IDE), Neprilysin (NEP), and matrix
metalloproteinase 2 and 9 (MMP2 and MMP9). Individual
primers were designed using Harvard Medical School Primer
Bank. qRT-PCR was performed using the Fast SYBR Green
Master Mix (Applied Biosystems) in ABI 7900HT (Applied
Biosystems) with the default thermal cycling program. Dissociation curves were analyzed after qPCR assay to confirm
primer efficacy. Relative mRNA levels were calculated using
JEM Vol. 213, No. 5

the ΔΔCt method, normalizing cDNA levels to endogenous
mouse GAPDH. Student’s t tests with p-value correction for
multiple comparisons were used to analyze changes in gene
expression using the GraphPad Prism 6 software.
LRP1 protein levels in brain tissue.Hippocampi from control
and XR9576-treated mice were lysed in buffer containing
150 mM NaCl, 50 mM Tris, 0.5% deoxycholic acid, 1% Triton X-100, 0.1% SDS, 2.5 mM EDTA, and broad spectrum
protease inhibitors. Protein concentration was determined in
each sample using a Micro BCA Protein Assay kit (Thermo
Fisher Scientific). 15 µg of protein for each sample was used
for SDS-PAGE using 4–12% Bis-Tris gels with MES running
buffer (Life Technologies). Rabbit polyclonal anti-LRP1 antibody was produced in G. Bu’s laboratory (Mayo Clinic,
Jacksonville, FL), followed by goat anti–rabbit HRP (Santa
Cruz Biotechnology).As a loading control, blots were stripped
and reprobed with mouse anti-GAPDH (Sigma-Aldrich) and
sheep anti–mouse peroxidase (GE Life Sciences). Blots were
imaged on a ImageStation 440CF (Kodak) and bands quantified using 1D image analysis software (Kodak). LRP1 bands
were normalized to GAPDH bands, and then for each gel the
control-treated and XR9576-treated tissues were normalized
to the mean of control bands intensity. LRP1 protein levels
were compared between groups by unpaired Student’s t test.
Compound E and XR9576 levels in brain tissue.Samples
were extracted with indicated volume of 45% methanol/45%
acetonitrile/8% water/2% formic acid containing 1 µM
LY411575 as internal standard so that each hemisphere was
extracted at a concentration of 200 mg/ml. After lysis by
shaking for 5 min at 20 Hz in the TissueLyserII (QIAGEN)
with a 4-mm stainless steel ball, samples were centrifuged and
then filtered through a 0.8-µm PES spin filter (Sartorius). Filtered samples were diluted 1:20 with LC-MS grade water
and centrifuged to remove any particulates. Samples were analyzed on a Q-Exactive Mass Spectrometer (Thermo Fisher
Scientific) operated in positive profile mode at a resolution
setting of 70,000 with a scan range of m/z 100–500. Spectra
were internally calibrated using the lock mass feature against
ever present airborne contaminants.The system was equipped
with a 1200 Capillary LC (Agilent) and a 0.5 × 100 mm 3 µm
PLRPS column (Higgins Analytical). Solvents were 100%
water (A) and acetonitrile (B) with 0.1% formic acid. The
chromatographic gradient was as follows: 0% B from 0–4 min
followed by a linear ramp up to 100% B over 6 min, a hold
at 100% B for 3 min, a 2-min ramp back down to 0% B, and,
finally, a reequilibration time of 15 min. 1 µl of sample was
injected such that 50 fmol of internal standard was loaded on
column each time for data normalization. Data were analyzed
using the QuanBrowser application of Xcalibur (Thermo
Fisher Scientific). Compound E and XR9576 concentrations
in mouse brain were calculated based on comparing normalized area counts with an external calibration curve prepared
in control mouse brain extract.
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Statistical analysis.All in vitro measurements were performed in triplicate and the mean of the three SWV scans
was used for analysis. All current responses recorded were
subtracted from background and fit to baseline for peak analysis using CH Instruments software. Results are expressed as
mean ± SE. Differences in clearance rates between groups
were analyzed in GraphPad Prism software using T-tests; repeated measures ANOVA with Bonferroni post-hoc tests was
used to analyze percent changes in baseline levels over time.
Statistical significance in all analyses was set at P < 0.05.
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